* Alfacell Corp., of Bloomfield, N.J., said in vitro findings publishedin the Aug. 23, 1996, Journal of Biological Chemistry showedOnconase, an anticancer ribonuclease, inhibited production of HIV-1in several persistently infected human cell lines. It said the drugpreferentially degraded viral RNA while not affecting normal cellularribosomal RNA and messenger RNA.

* Neurogen Corp., of Branford, Conn., said interim results of a dose-escalating Phase I trial of its neuropeptide Y antagonist, NGD 95-1,showed the agent was safe and well tolerated across a broad doserange. Preliminary pharmacokinetics also were conducted. The drugis being developed with Pfizer Inc., of New York.

Jim SeechukCommunity of Science, Inc1615 Thames St.Baltimore MD 21231410-563-5383jcs@bestpl.hcf.jhu.edu

(c) 1997 American Health Consultants. All rights reserved.

No Comments